Damora Therapeutics, Inc. (DMRA): M&A transaction — Galecto acquires global rights to BRM-1420 dual ENL-YEATS/FLT3 inhibitor for AML

Damora Therapeutics, Inc.

Galecto issued 62,594 common shares and 160.562 Series A convertible preferred shares (convertible into 160,562 common) to Bridge Medicines.
BRM-1420 is a novel dual ENL-YEATS and FLT3 inhibitor targeting multiple genetic subsets of acute myeloid leukemia (AML).
Carl Goldfischer, Galecto's Chairman, also serves as Executive Chairman of Bridge Medicines (related-party transaction).
Pro forma impact: cash reduced by $2.68M; total consideration valued at stock issuance; assumes liabilities.
Stockholder approval required for conversion of preferred shares; Bridge Medicines restricted from selling shares for 12 months.

item 1.01 item 2.01 item 3.02 item 5.02 item 5.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Damora Therapeutics, Inc. completed an acquisition involving Bridge Medicines LLC for 62,594 shares of common stock and 160.562 shares of Series A non-voting convertible preferred stock (closed 2024-10-07).

Action: acquisition
Counterparty: Bridge Medicines LLC
Consideration: 62,594 shares of common stock and 160.562 shares of Series A non-voting convertible preferred stock
Closing: 2024-10-07

Exact text from the filing

Agreement, at the closing of the Asset Purchase (the “ Closing ”), as consideration to Bridge Medicines for the Asset Purchase, the Company (a) issued to Bridge Medicines (i) 62,594 shares (the “ Common Stock Payment Shares ”) of the Company’s common stock, par value $0.00001 per share (the “ Common Stock ”), and (ii) 160.562 shares (the “ Preferred Stock

View on SEC.gov

Browse all m&a transactions →

Damora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-113091

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.